Roivant Sciences has delivered a very strong multi year share price run, which now puts a spotlight on whether the current market value lines up with what its balance sheet actually supports. With that backdrop, the live question for you is how well the stock price today lines up with Roivant Sciences' book value.
-
Over the past 5 years the stock has returned about 393%, which puts real weight on the question of how much book value is backing each dollar of market value today.
-
Progress toward launching brepocitinib and advancing other autoimmune and pulmonary candidates, alongside the US$950m settlement from Moderna, can shift expectations for future capital needs and how quickly the business might build equity on its balance sheet.
-
There is a second opinion on Roivant Sciences worth weighing. See what analysts think Roivant Sciences's shares could be worth .
The issue now is whether the current share price is adequately supported by Roivant Sciences' book value when compared with the industry average.
To evaluate Roivant Sciences in terms of balance sheet support, compare it with other companies screened for solid balance sheet and fundamentals stocks screener (25 results) .
Has Roivant Sciences Run Too Far on Book Value?
P/B fits Roivant Sciences because the story today leans heavily on its balance sheet and pipeline assets rather than established earnings. The shares trade around 5.7x book value, compared with a biotech industry average near 1.8x and a peer group closer to 4.8x, so investors are paying a clear premium for each dollar of equity.
Because Roivant is preparing for a busy second half of 2026 with the planned brepocitinib launch and broader pipeline progress, the market is already pricing in a lot of optimism relative to typical biotechs. That premium multiple screens as above the sector level and suggests you need strong conviction in the durability of the drug portfolio and the use of the Moderna settlement cash to be comfortable at this price. Explore the numbers behind Roivant Sciences's P/B valuation .
The Roivant Sciences Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Roivant Sciences pick up where the P/B puzzle leaves off and outline which paths for growth, margins and earnings would need to occur for the stock to be worth materially more or less than it is today on the market. Rather than stopping at a single ratio or model output, they explain the future that those numbers are assuming so you can track how Roivant Sciences' actual progress compares with that story over time on the Community page.
Roivant Sciences splits opinion, with some holders arguing the stock still underappreciates its drug portfolio while others see the valuation baking in near perfect execution.
Bull case: 31% undervalued
"Roivant Sciences now has its first commercial rare disease product with LISRAYA in dermatomyositis, which carries list pricing of US$35,000 for a 30 day supply and financial assistance programs that aim to keep out of pocket costs low, creating a potential high value revenue base..."
Discover why this Narrative puts Roivant Sciences at 31% undervalued .
Bear case: 235% overvalued
"Roivant is a brilliant asset flipper, but at a $24B+ valuation, the market has priced in flawless legal victories and immediate market share capture..."
Explore why this Narrative puts Roivant Sciences at 235% overvalued .
One more Roivant Sciences piece that could change how you see the whole story
Balance sheet ratios and book value only tell part of the picture. Professional coverage also sketches out where this business might be a few years from now, which gives you a different yardstick to compare with today's price. Explore where analysts expect Roivant Sciences to be in a few years .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ROIV .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
